Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
15 Juin 2023 - 12:30PM
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to
unraveling the mysteries of the brain to treat neuroscience
diseases, today announced the appointment of Paul Burgess as chief
business development and strategic operations officer, effective
June 20, 2023.
“I am so pleased to welcome Paul to Cerevel as our chief
business development and strategic operations officer, with his
proven track record of success in the biotech and pharmaceutical
industry,” said Ron Renaud, president and chief executive officer
of Cerevel Therapeutics. “Paul brings more than 20 years of
corporate development and operational experience to the
organization, and his insights and expertise will be indispensable
as we seek to become the premier neuroscience
company.”
“I look forward to joining Cerevel during this pivotal time and
supporting the mission to transform the lives of people living with
some of the most devastating neuroscience diseases,” said Mr.
Burgess. “Cerevel’s patient-centered approach holds great promise
for delivering new treatment options for schizophrenia, Parkinson’s
disease, and epilepsy."
About Paul BurgessPaul Burgess is a
biotechnology executive with over 20 years of experience working at
both start-up companies and larger pharmaceutical organizations.
Mr. Burgess’s most recent role was chief operating officer and
chief legal officer of Translate Bio. At Translate Bio, he led
business development, legal, program management, quality, technical
operations and partner collaborations. He joined Translate Bio in
2015 and remained until 2021, when the company was sold to Sanofi
for $3.2 billion.
Prior to Translate Bio, Mr. Burgess worked in a legal role at a
number of companies including Scholar Rock, Civitas Therapeutics,
BIND Therapeutics and Transform Pharmaceuticals. Earlier in his
career, he also worked in the lab at Genetics Institute.
About Cerevel TherapeuticsCerevel Therapeutics
is dedicated to unraveling the mysteries of the brain to treat
neuroscience diseases. The company is tackling diseases by
combining its deep expertise in neurocircuitry with a focus on
targeted receptor subtype selectivity and a differentiated approach
to pharmacology. Cerevel Therapeutics has a diversified pipeline
comprised of five clinical-stage investigational therapies and
several preclinical compounds with the potential to treat a range
of neuroscience diseases, including schizophrenia, Alzheimer’s
disease psychosis, epilepsy, panic disorder, and Parkinson’s
disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is
advancing its current research and development programs while
exploring new modalities through internal research efforts,
external collaborations, or potential acquisitions. For more
information, visit www.cerevel.com.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that are based on management’s beliefs and assumptions
and on information currently available to management. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about:
the potential attributes and benefits of our product candidates and
the format, timing and objectives of our product development
activities and clinical trials. We cannot assure you that the
forward-looking statements in this press release will prove to be
accurate. Furthermore, if the forward-looking statements prove to
be inaccurate, the inaccuracy may be material. Actual performance
and results may differ materially from those projected or suggested
in the forward-looking statements due to various risks and
uncertainties, including, among others: clinical trial results may
not be favorable; uncertainties inherent in the product development
process (including with respect to the timing of results and
whether such results will be predictive of future results); the
impact of COVID-19, the post-COVID environment and other factors on
the timing, progress and results of clinical trials; our ability to
recruit and enroll suitable patients in our clinical trials;
whether and when, if at all, our product candidates will receive
approval from the FDA or other regulatory authorities, and for
which, if any, indications; competition from other biotechnology
companies; uncertainties regarding intellectual property
protection; and other risks identified in our SEC filings,
including those under the heading “Risk Factors” in our Quarterly
Report on Form 10-Q filed with the SEC on May 3, 2023 and our
subsequent SEC filings. In light of the significant uncertainties
in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any
specified time frame, or at all. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media Contact:Anna RobinsonCerevel Therapeutics
anna.robinson@cerevel.com
Investor Contact:Matthew CalistriCerevel
Therapeuticsmatthew.calistri@cerevel.com
Cerevel Therapeutics (NASDAQ:CERE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cerevel Therapeutics (NASDAQ:CERE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024